Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer

Cancer Cell International

Jianjun Qian¹  Huo Tan²  Xiangmin Ding¹  Lihua Xu² 

[1] Department of Hepatopancreatobiliary Surgery, Subei People’s Hospital, Yangzhou, Jiangsu 225000, China;Center of Oncology and Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510230, China

关键词: Prognosis;    Pancreatic cancer;    MMP-2;    B7-H3 expression;   

Others  :  793146
DOI  :  10.1186/1475-2867-13-81

 received in 2013-07-09, accepted in 2013-08-03,  发布年份 2013

【 摘 要 】

Background

B7-H3 and matrix metalloproteinases 2 (MMP-2) are reported highly expressed in malignant tumor, we investigate the relationship between B7-H3 expression and MMP-2 on malignant behavior and prognosis predictable value in pancreatic cancer.

Methods

We tested the expressions of B7-H3 and MMP-2 protein in 45 pancreatic surgical resected cancer samples; meanwhile, the clinicopathological data of enrolled patients were obtained for correlation analysis to obtain their relationship with pancreatic cancer progress.

Results

The expression of B7-H3 was up-regulated with infiltrating depth, lymph node metastasis and TNM stage (P < 0.01). Positive expression rate of MMP-2 in pancreatic cancer tissues was 44.35%, whereas negative in normal pancreatic tissues. Multivariate analysis of Logistic regression showed B7-H3 and MMP-2 expressions were hazardous makers correlated with infiltrating depth (P < 0.05).

Conclusion

Our study showed combined detections of B7-H3 and MMP2 protein expression could identify patients at high risk in disease recurrence and prognosis more efficiently.

【 授权许可】

   
2013 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Laheru D, Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005, 5:459-467.
• [2]Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, Wu LY, He J: Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res 2012, 24:171-180.
• [3]Labianca R, Merelli B, Mosconi S: Treatment of advanced pancreatic cancer. Ann Oncol 2012, 23(Suppl 10):x139-x140.
• [4]Grover S, Syngal S: Hereditary pancreatic cancer. Gastroenterology 2010, 139(1080):1076-1080. e1071-1072
• [5]Gonda TA, Lucas A, Saif MW: Screening and detection of pancreatic cancer. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP 2011, 12:322-324.
• [6]Wang J, Liu L, Xie L, Xiang G, Zhou Y: Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation. Int J Mol Med 2013, 31:59-66.
• [7]Xu YH, Zhang GB, Wang JM, Hu HC: B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 2010, 31:980-986.
• [8]Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009, 101:1709-1716.
• [9]Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B, Zhang X: Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer 2009, 66:245-249.
• [10]Arigami T, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S: B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci 2011, 102:1019-1024.
• [11]Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB, Zhang XG: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006, 12:457-459.
• [12]Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O: B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2012, 130:2282-2290.
• [13]Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
• [14]Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000, 36:1621-1630.
• [15]Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
• [16]Kjellman M, Enberg U, Hoog A, Larsson C, Holst M, Farnebo LO, Sato H, Backdahl M: Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas. World J Surg 1999, 23:237-242.
• [17]Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000, 24:334-340.
• [18]Ferretti S, Patriarca S, Carbone A, Zanetti R: [TNM classification of malignant tumours, VII edition 2009. Changes and practical effects on cancer epidemiology]. Epidemiol Prev 2009, 2010(34):125-128.
• [19]Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24:4421-4432.
• [20]Guo RP, Zhong C, Shi M, Zhang CQ, Wei W, Zhang YQ, Li JQ: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:547-555.
• [21]Li H, Wang C, Guo G, Gao C, Wu Y, Chen Y: The characteristic expression of B7-associated proteins in Langerhans cell sarcoma. Acta Histochem 2012, 114:733-743.
• [22]Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, Zhang ZX, Zhang GB, Zhang XG, Zhao H: B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med 2013, 31:283-291.
• [23]Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
• [24]Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006, 53:143-151.